Genentech BioOncology Co-pay Card

Genentech BioOncology Co-Pay Card

At Genentech BioOncology, we are committed to helping patients access the therapies they need. We've made some changes to the Genentech BioOncology Co-pay Card that will help simplify patient enrollment.

How does this card work?

There is now one card for all of our Genentech cancer therapies, with one set of eligibility criteria, one set of benefits and one number to call.

The card reduces out-of-pocket costs for your eligible patients, regardless of income.* Out-of-pocket costs are defined as the co-pay, co-insurance or deductible for your patients' therapy. This must clearly be defined on the Explanation of Benefits when submitted.

  • *If your patient's annual household income is >$100,000, the card limit is reduced. See "How much does the card cover?" below for details.

Find out if your patients are eligible

Eligible Not Eligible
  • Covered by commercial insurance
  • Age 18 years or older
  • Participating in Medicare, Medicaid, Medigap, VA, DoD, and Tricare
  • Uninsured (refer to Genentech® Access to Care Foundation [GATCF]) or currently participating in GATCF
  • Patients taking most Genentech cancer therapies must meet certain medical criteria to be eligible.

What is the patient's responsibility?

Patient's responsibility 20% (but no more than $100) of the out-of-pocket costs for each Genentech cancer treatment (per prescription or infusion)
Card covers At least 80% of the out-of-pocket costs for each Genentech cancer treatment (per prescription or infusion)
Card limit Up to $24,000 per year‡§
  • Patients who make a household income of >$100,000 per year have a limit of $9,000.Patients only need to provide a verbal statement to verify their income when they enroll. Proof of documentation at a later date may be required.
  • §Some patients may be on more than one Genentech BioOncology therapy, and the benefits above apply to each product individually. Coverage eligibility for multiple products is determined at enrollment.

Enrolling patients

If you want to enroll your patients or have any questions, call 855-MYCOPAY (855-692-6729) from 9 AM - 8 PM ET, Monday through Friday or visit For additional co-pay materials, including cards and brochures, contact your BioOncology sales representative.

RITUXAN: Access Solutions. Treatment made possible.

What about my RITUXAN patients
who are not eligible for the Genentech BioOncology Co-pay Card?

We develop therapies for serious or life-threatening medical conditions and we believe they should be accessible for the patients who need them. At Rituxan® Access Solutions, we are here to help find a way for you to get RITUXAN to your patients, regardless of their ability to pay for it. A Rituxan Access Solutions Specialist can refer ineligible patients to an independent, non-profit organization (INO)ll that may be able to help. Uninsured patients may be able to get free therapy through GATCF.

Contact Rituxan Access Solutions via phone at
(888) 249-4918 6 am-5 pm PT, Monday-Friday
Or visit our website at

  • llGenentech and Biogen Idec do not influence or control the operations of these INOs, but Rituxan Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient's diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Rituxan Access Solutions. The INOs to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.


RITUXAN® (Rituximab) is indicated for the treatment of patients with:

  • Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to RITUXAN in combination with chemotherapy, as single-agent maintenance therapy
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
  • Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC)

RITUXAN is not recommended for use in patients with severe, active infections.

Important Safety Information



  • Infusion Reactions: RITUXAN administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue RITUXAN infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions
  • Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving RITUXAN
  • Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with RITUXAN, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with RITUXAN. Discontinue RITUXAN and concomitant medications in the event of HBV reactivation
  • Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving RITUXAN

Warnings and Precautions

Tumor Lysis Syndrome

  • Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12−24 hours after the first infusion of RITUXAN in patients with NHL. A high number of circulating malignant cells (≥25,000/mm3) or high tumor burden, confers a greater risk of TLS. Administer aggressive intravenous hydration and anti hyperuricemic therapy in patients at high risk for TLS


  • Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of RITUXAN-based therapy. Discontinue RITUXAN for serious infections and institute appropriate anti infective therapy


  • Discontinue infusions for serious or life threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of RITUXAN for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina


  • Severe, including fatal, renal toxicity can occur after RITUXAN administration in patients with NHL. Monitor closely for signs of renal failure and discontinue RITUXAN in patients with a rising serum creatinine or oliguria

Bowel Obstruction and Perforation

  • Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving RITUXAN in combination with chemotherapy. Evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur


  • The safety of immunization with live viral vaccines following RITUXAN therapy has not been studied and vaccination with live virus vaccines is not recommended

Laboratory Monitoring

  • Obtain complete blood counts (CBC) prior to each RITUXAN course

Additional Important Safety Information

  • The most common Grade 3 or 4 adverse reactions in clinical trials of NHL and CLL were infusion reactions, neutropenia, leukopenia, anemia, thrombocytopenia, and infections. Additionally, lymphopenia and lung disorder were seen in NHL trials; and febrile neutropenia, pancytopenia, hypotension, and hepatitis B were seen in CLL trials
  • The most common adverse reactions (incidence ≥25%) in clinical trials of NHL and CLL were infusion reactions. Additionally, fever, lymphopenia, chills, infection, and asthenia were seen in NHL trials; and neutropenia was seen in CLL trials
  • Pregnancy: Category C. There are no adequate and well-controlled studies of rituximab in pregnant women

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

You may report side effects to the FDA at (800) FDA-1088 or

You may also report side effects to Genentech at (888) 835-2555.